A detailed history of Charles Schwab Investment Management Inc transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 110,720 shares of KALV stock, worth $969,907. This represents 0.0% of its overall portfolio holdings.

Number of Shares
110,720
Previous 110,594 0.11%
Holding current value
$969,907
Previous $1.3 Million 1.54%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$9.46 - $15.39 $1,191 - $1,939
126 Added 0.11%
110,720 $1.28 Million
Q2 2024

Aug 12, 2024

BUY
$10.35 - $12.49 $335,919 - $405,375
32,456 Added 41.54%
110,594 $1.3 Million
Q1 2024

May 08, 2024

SELL
$11.07 - $16.04 $25,604 - $37,100
-2,313 Reduced 2.88%
78,138 $926,000
Q4 2023

Feb 06, 2024

BUY
$7.58 - $12.25 $115,951 - $187,388
15,297 Added 23.48%
80,451 $985,000
Q2 2023

Aug 09, 2023

BUY
$7.73 - $10.57 $9,948 - $13,603
1,287 Added 2.02%
65,154 $586,000
Q1 2023

May 11, 2023

BUY
$6.3 - $8.39 $4,731 - $6,300
751 Added 1.19%
63,867 $501,000
Q3 2022

Nov 14, 2022

BUY
$9.85 - $16.83 $2,137 - $3,652
217 Added 0.34%
63,116 $916,000
Q2 2022

Aug 15, 2022

BUY
$8.16 - $15.1 $36,589 - $67,708
4,484 Added 7.68%
62,899 $619,000
Q1 2022

May 13, 2022

BUY
$11.2 - $16.97 $11,200 - $16,970
1,000 Added 1.74%
58,415 $862,000
Q4 2021

Feb 11, 2022

BUY
$12.36 - $18.28 $65,718 - $97,194
5,317 Added 10.21%
57,415 $760,000
Q3 2021

Nov 16, 2021

BUY
$17.11 - $24.49 $67,362 - $96,417
3,937 Added 8.17%
52,098 $910,000
Q2 2021

Aug 16, 2021

BUY
$23.12 - $29.91 $29,223 - $37,806
1,264 Added 2.7%
48,161 $1.15 Million
Q1 2021

May 17, 2021

BUY
$14.69 - $42.57 $195,523 - $566,606
13,310 Added 39.63%
46,897 $1.21 Million
Q4 2020

Feb 16, 2021

BUY
$12.88 - $19.47 $33,449 - $50,563
2,597 Added 8.38%
33,587 $638,000
Q3 2020

Nov 13, 2020

SELL
$9.83 - $13.99 $14,066 - $20,019
-1,431 Reduced 4.41%
30,990 $391,000
Q2 2020

Aug 14, 2020

BUY
$6.75 - $12.89 $17,496 - $33,410
2,592 Added 8.69%
32,421 $393,000
Q4 2019

Feb 07, 2020

BUY
$10.31 - $17.81 $26,146 - $45,166
2,536 Added 9.29%
29,829 $532,000
Q2 2019

Aug 09, 2019

BUY
$18.44 - $30.89 $503,282 - $843,080
27,293 New
27,293 $605,000

Others Institutions Holding KALV

About KalVista Pharmaceuticals, Inc.


  • Ticker KALV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,602,000
  • Market Cap $216M
  • Description
  • KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...
More about KALV
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.